Annals of Oncology最新文献

筛选
英文 中文
Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse. 伊马替尼辅助治疗持续六年可提高高复发风险 GIST 的无病生存率。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-21 DOI: 10.1016/j.annonc.2024.09.018
J-Y Blay, N Penel, C Schiffler, S Chabaud, D Perol, A Le Cesne
{"title":"Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse.","authors":"J-Y Blay, N Penel, C Schiffler, S Chabaud, D Perol, A Le Cesne","doi":"10.1016/j.annonc.2024.09.018","DOIUrl":"https://doi.org/10.1016/j.annonc.2024.09.018","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to the Letter to the Editor "Odronextamab against relapsed or refractory follicular lymphoma" by Y. Shimazu. 回复 Y. Shimazu 写给编辑的信 "Odronextamab 对抗复发或难治性滤泡淋巴瘤"。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-21 DOI: 10.1016/j.annonc.2024.10.016
T M Kim, A Chaudhry, H Mohamed, B Shen, S Ambati
{"title":"Reply to the Letter to the Editor \"Odronextamab against relapsed or refractory follicular lymphoma\" by Y. Shimazu.","authors":"T M Kim, A Chaudhry, H Mohamed, B Shen, S Ambati","doi":"10.1016/j.annonc.2024.10.016","DOIUrl":"10.1016/j.annonc.2024.10.016","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy. 采用新辅助类固醇疗法治疗早期三阴性乳腺癌的 TNBC-DX 基因组检测。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-16 DOI: 10.1016/j.annonc.2024.10.012
M Martín, S R Stecklein, O Gluz, G Villacampa, M Monte-Millán, U Nitz, S Cobo, M Christgen, F Brasó-Maristany, E L Álvarez, I Echavarría, B Conte, S Kuemmel, C Bueno-Muiño, Y Jerez, R Kates, M Cebollero, C Kolberg-Liedtke, O Bueno, J Á García-Saenz, F Moreno, E-M Grischke, H Forstbauer, M Braun, M Warm, J Hackmann, C Uleer, B Aktas, C Schumacher, R Wuerstleins, M Graeser, C Zu Eulenburg, H H Kreipe, H Gómez, T Massarrah, B Herrero, L Paré, U Bohn, S López-Tarruella, A Vivancos, E Sanfeliu, J S Parker, C M Perou, P Villagrasa, A Prat, P Sharma, N Harbeck
{"title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.","authors":"M Martín, S R Stecklein, O Gluz, G Villacampa, M Monte-Millán, U Nitz, S Cobo, M Christgen, F Brasó-Maristany, E L Álvarez, I Echavarría, B Conte, S Kuemmel, C Bueno-Muiño, Y Jerez, R Kates, M Cebollero, C Kolberg-Liedtke, O Bueno, J Á García-Saenz, F Moreno, E-M Grischke, H Forstbauer, M Braun, M Warm, J Hackmann, C Uleer, B Aktas, C Schumacher, R Wuerstleins, M Graeser, C Zu Eulenburg, H H Kreipe, H Gómez, T Massarrah, B Herrero, L Paré, U Bohn, S López-Tarruella, A Vivancos, E Sanfeliu, J S Parker, C M Perou, P Villagrasa, A Prat, P Sharma, N Harbeck","doi":"10.1016/j.annonc.2024.10.012","DOIUrl":"10.1016/j.annonc.2024.10.012","url":null,"abstract":"<p><strong>Background: </strong>Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of this study was to evaluate the association between TNBC-DX and efficacy outcomes [pathologic complete response (pCR), distant disease-free survival (DDFS) or event-free survival (EFS), and overall survival (OS)] in the validation cohorts.</p><p><strong>Methods: </strong>Information from 1259 patients with early-stage TNBC (SCAN-B, CALGB-40603, and BrighTNess) was used to establish the TNBC-DX scores. Independent validation of TNBC-DX was carried out in three studies: (i) WSG-ADAPT-TN; (ii) MMJ-CAR-2014-01; and (iii) NeoPACT, including 527 patients with stage I-III TNBC undergoing neoadjuvant chemotherapy. In WSG-ADAPT-TN, patients were randomized to receive nab-paclitaxel plus gemcitabine or carboplatin. In MMJ-CAR-2014-01, patients received carboplatin plus docetaxel. In NeoPACT, patients received carboplatin plus docetaxel and pembrolizumab.</p><p><strong>Results: </strong>TNBC-DX test was created incorporating the 10-gene Core Immune Gene module, the 4-gene tumor cell proliferation signature, tumor size, and nodal staging. In the two independent validation cohorts without pembrolizumab, the TNBC-DX pCR score was significantly associated with pCR after adjustment for clinicopathological variables and treatment regimen [odds ratio per 10-unit increment 1.34, 95% confidence interval (CI) 1.20-1.52, P < 0.001]. pCR rates for the TNBC-DX pCR-high, pCR-medium, and pCR-low categories were 56.3%, 53.6%, and 22.5% respectively (odds ratio for pCR-high versus pCR-low 3.48, 95% CI 1.72-7.15, P < 0.001). In addition, the TNBC-DX risk score was significantly associated with DDFS [hazard ratio (HR) high-risk versus low-risk 0.24, 95% CI 0.15-0.41, P < 0.001] and OS (HR 0.19, 95% CI 0.11-0.35, P < 0.001). In the validation cohort with pembrolizumab, the TNBC-DX scores were significantly associated with pCR, EFS, and OS.</p><p><strong>Conclusions: </strong>TNBC-DX predicts pCR to neoadjuvant taxane-carboplatin in stage I-III TNBC and helps to forecast the patient's long-term survival in the absence of neoadjuvant anthracycline-cyclophosphamide, and independent of pembrolizumab use.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chi-square and P-values versus machine learning feature selection. Chi-Squared 和 P-Values 与机器学习特征选择的对比。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-12 DOI: 10.1016/j.annonc.2024.10.013
Y Takefuji
{"title":"Chi-square and P-values versus machine learning feature selection.","authors":"Y Takefuji","doi":"10.1016/j.annonc.2024.10.013","DOIUrl":"10.1016/j.annonc.2024.10.013","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Authors' reply to the Letters to the Editor discussing main outcomes of the PRODIGE 23 study. 作者对讨论 PRODIGE 23 研究主要成果的致编辑信的回复。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-12 DOI: 10.1016/j.annonc.2024.10.007
T Conroy, S Gourgou, C Borg
{"title":"Authors' reply to the Letters to the Editor discussing main outcomes of the PRODIGE 23 study.","authors":"T Conroy, S Gourgou, C Borg","doi":"10.1016/j.annonc.2024.10.007","DOIUrl":"10.1016/j.annonc.2024.10.007","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising response to lurbinectedin in NUT carcinoma: a case report and review of emerging therapeutic strategies. NUT Carcinoma 对 Lurbinectedin 的良好反应:病例报告和新兴治疗策略综述。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-11 DOI: 10.1016/j.annonc.2024.10.008
M V Sánchez Becerra, C Escudero Iriarte, C Travert, T V Tian, B Besse
{"title":"Promising response to lurbinectedin in NUT carcinoma: a case report and review of emerging therapeutic strategies.","authors":"M V Sánchez Becerra, C Escudero Iriarte, C Travert, T V Tian, B Besse","doi":"10.1016/j.annonc.2024.10.008","DOIUrl":"10.1016/j.annonc.2024.10.008","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to rethink platinum choices in the era of immunotherapy in lung cancer. 在肺癌免疫疗法时代,是时候重新考虑铂类药物的选择了。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-11 DOI: 10.1016/j.annonc.2024.10.009
E Harris, N F Taflin, A Chitkara, M Tagliamento, C M Bestvina, C V Vakkalagadda, B Besse, R Thawani
{"title":"Time to rethink platinum choices in the era of immunotherapy in lung cancer.","authors":"E Harris, N F Taflin, A Chitkara, M Tagliamento, C M Bestvina, C V Vakkalagadda, B Besse, R Thawani","doi":"10.1016/j.annonc.2024.10.009","DOIUrl":"10.1016/j.annonc.2024.10.009","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimising treatment strategies in metastatic colorectal cancer: insights from CAIRO4. 优化转移性结直肠癌的治疗策略:CAIRO4 的启示。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-11 DOI: 10.1016/j.annonc.2024.10.004
H G Güzel, Y İlhan, A H Önder
{"title":"Optimising treatment strategies in metastatic colorectal cancer: insights from CAIRO4.","authors":"H G Güzel, Y İlhan, A H Önder","doi":"10.1016/j.annonc.2024.10.004","DOIUrl":"10.1016/j.annonc.2024.10.004","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer? PFS、OS 或毒性:治疗表皮生长因子受体突变肺癌的最重要因素是什么?
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-11 DOI: 10.1016/j.annonc.2024.10.010
T Nishimura, H Fujimoto
{"title":"PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?","authors":"T Nishimura, H Fujimoto","doi":"10.1016/j.annonc.2024.10.010","DOIUrl":"10.1016/j.annonc.2024.10.010","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Pembrolizumab 联合化疗治疗晚期和复发性宫颈癌:根据随机 KEYNOTE-826 研究中贝伐单抗使用情况的最终分析。
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-10-10 DOI: 10.1016/j.annonc.2024.10.002
D Lorusso, N Colombo, C Dubot, M V Cáceres, K Hasegawa, R Shapira-Frommer, P Salman, E Yañez, M Gümüş, M Olivera, V Samouëlian, V Castonguay, A Arkhipov, K Li, S Toker, C Tekin, K S Tewari, B J Monk
{"title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.","authors":"D Lorusso, N Colombo, C Dubot, M V Cáceres, K Hasegawa, R Shapira-Frommer, P Salman, E Yañez, M Gümüş, M Olivera, V Samouëlian, V Castonguay, A Arkhipov, K Li, S Toker, C Tekin, K S Tewari, B J Monk","doi":"10.1016/j.annonc.2024.10.002","DOIUrl":"10.1016/j.annonc.2024.10.002","url":null,"abstract":"<p><strong>Background: </strong>In KEYNOTE-826 (NCT03635567), pembrolizumab plus chemotherapy (±bevacizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with persistent, recurrent, or metastatic cervical cancer. This exploratory analysis examined outcomes in patient subgroups defined by bevacizumab use.</p><p><strong>Patients and methods: </strong>Eligible adult patients had persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not previously treated with chemotherapy and not amenable to curative treatment; measurable disease per RECIST v1.1; and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomly allocated 1 : 1 to pembrolizumab 200 mg every 3 weeks or placebo for up to 35 cycles plus chemotherapy (±bevacizumab 15 mg/kg). Dual primary endpoints were OS and PFS per RECIST v1.1 by investigator assessment. Outcomes were assessed in subgroups defined by bevacizumab use. Hazard ratios (HRs) and 95% confidence intervals (CIs) were based on a stratified Cox regression model.</p><p><strong>Results: </strong>A total of 617 patients were randomly assigned [pembrolizumab arm, n = 308 (63.6% with bevacizumab); placebo arm, n = 309 (62.5% with bevacizumab)]. The most common reason for bevacizumab exclusion was medical contraindication (75.9%). Among patients who received bevacizumab, HRs (95% CIs) for PFS favored the pembrolizumab arm in the programmed cell death-ligand 1 combined positive score ≥1 [0.56 (0.43-0.73)] and all-comer [0.57 (0.45-0.73)] populations; OS results were 0.60 (0.45-0.79) and 0.61 (0.47-0.80), respectively. Among patients who did not receive bevacizumab, HRs (95% CIs) for PFS also favored the pembrolizumab arm in the programmed cell death-ligand 1 combined positive score ≥1 [0.61 (0.44-0.85)] and all-comer [0.69 (0.50-0.94)] populations; OS results were 0.61 (0.44-0.85) and 0.67 (0.49-0.91), respectively. Among patients who received bevacizumab, grade ≥3 treatment-related adverse events occurred in 74.0% of patients in the pembrolizumab arm and 66.8% in the placebo arm.</p><p><strong>Conclusion: </strong>Pembrolizumab plus chemotherapy prolonged PFS and OS and had manageable safety compared with placebo plus chemotherapy in patient subgroups defined by bevacizumab use.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142405946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信